LIAN.Y Stock Overview
A biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
LianBio Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.30 |
| 52 Week High | US$4.99 |
| 52 Week Low | US$0.24 |
| Beta | -0.014 |
| 11 Month Change | 5.73% |
| 3 Month Change | -12.93% |
| 1 Year Change | -92.69% |
| 33 Year Change | -97.60% |
| 5 Year Change | n/a |
| Change since IPO | -97.84% |
Recent News & Updates
Recent updates
With No Cure In Sight, Drugs Firm LianBio Begins Exit Strategy
Feb 23LianBio (NASDAQ:LIAN) Is In A Good Position To Deliver On Growth Plans
Jul 20
We're Hopeful That LianBio (NASDAQ:LIAN) Will Use Its Cash Wisely
Apr 05We Think LianBio (NASDAQ:LIAN) Can Afford To Drive Business Growth
Dec 20Companies Like LianBio (NASDAQ:LIAN) Are In A Position To Invest In Growth
Sep 02Will LianBio (NASDAQ:LIAN) Spend Its Cash Wisely?
May 17LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market
Mar 03Here's Why LianBio (NASDAQ:LIAN) Must Use Its Cash Wisely
Feb 01Shareholder Returns
| LIAN.Y | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.9% | 4.0% | 2.2% |
| 1Y | -92.7% | 18.3% | 32.6% |
Return vs Industry: LIAN.Y underperformed the US Biotechs industry which returned 18.3% over the past year.
Return vs Market: LIAN.Y underperformed the US Market which returned 32.6% over the past year.
Price Volatility
| LIAN.Y volatility | |
|---|---|
| LIAN.Y Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: LIAN.Y has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: LIAN.Y's weekly volatility has decreased from 16% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 163 | Adam Stone | www.lianbio.com |
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn’s disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy.
LianBio Fundamentals Summary
| LIAN.Y fundamental statistics | |
|---|---|
| Market cap | US$31.38m |
| Earnings (TTM) | -US$87.98m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs LIAN.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LIAN.Y income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$87.98m |
| Earnings | -US$87.98m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.81 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did LIAN.Y perform over the long term?
See historical performance and comparison